• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>California management review >Responding to a Potentially Disruptive Technology: How Big Pharma Embraced Biotechnology
【24h】

Responding to a Potentially Disruptive Technology: How Big Pharma Embraced Biotechnology

机译：应对潜在破坏性技术：大型制药公司如何拥抱生物技术

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

How do incumbent firms respond over time to a potentially disruptive technology? This article documents the strategies of 12 large pharmaceutical firms over 25 years as they addressed the opportunity/threat of biotechnology. All showed awareness of biotechnology’s potential, but their response profiles varied dramatically in terms of timing (early/late) and focus (external/internal). Late movers mostly made large acquisitions to “catch up,” but early movers maintained their lead in terms of biotechnology-based drug sales and profitability, and those with a more “open” response profile performed better. This response involves a three-step process: building awareness (sensing), building capability (responding), and building commitment (scaling).
机译：随着时间的推移，老牌企业如何应对潜在的破坏性技术？本文记录了12家大型制药公司在25年内应对生物技术的机遇/威胁的战略。所有人都对生物技术的潜力有所了解，但是他们的反应方式在时间（早/晚）和关注（外部/内部）方面差异很大。后进者大多进行大型收购以“追赶”，但早进者在基于生物技术的药品销售和盈利能力方面保持领先地位，而响应方式更“开放”的企业则表现更好。该响应包括三个步骤：建立意识（感知），建立能力（响应）和建立承诺（扩展）。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号